NuCana PLC

Stock Chart, Company Information, and Scan Results

$4.55(as of Aug 13, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

NuCana PLC Company Information, Fundamentals, and Technical Indicators

Stock Price$4.55
Ticker SymbolNCNA
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees20
CountyUSA
Market Cap$1,736.4M
EBIDTA-17.2M
10-Day Moving Average6.44
P/E Ratio-1.72
20-Day Moving Average8.35
Forward P/E Ratio0.00
50-Day Moving Average12.93
Earnings per Share-1,007.55
200-Day Moving Average146.07
Profit Margin-Infinity%
RSI30.72
Shares Outstanding381.6M
ATR2.10
52-Week High2,158.00
Volume519,576
52-Week Low4.12
Most Recent Support Level4.12
Book Value4.2M
Most Recent Resistance Level5.70
P/B Ratio6.04
Upper Keltner13.08
P/S RatioInfinity
Lower Keltner3.62
Debt-to-Equity Ratio13.08
Next Earnings DateUnknown
Cash Surplus-3.3M
Next Ex-Dividend DateUnknown

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company is developing medicines to overcome the limitations of nucleoside analogs and generate anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer; Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer; and Phase 1 modular clinical trial for patients with advanced solid tumors and lung cancer. The company is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is based in Edinburgh, the United Kingdom.

NuCana PLC In Our Stock Scanner

As of Aug 15, 2025
example chart graphic
Scan Name: 52-Week LowScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Low Debt to Equity RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Mean ReversionScan Type: Stock Indicator Scans
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.